There is a known increased risk of skin cancer in the adult population after hematopoietic stem cell transplantation (HSCT). However, late dermatologic effects that children may experience after HSCT have not been well described. The primary objective of this study was to characterize nevi and skin cancers affecting children after allogeneic HSCT. A cross-sectional cohort study of 85 pediatric HSCT recipients and 85 controls matched for age, sex and skin phototype was performed at a single institution. All participants underwent a full skin examination. Median age at study visit was 13.8 years in HSCT patients with median time post-HSCT of 3.6 years. HSCT patients had significantly more nevi than control patients (median (range): 44 (0-150) vs 11 (0-94), Po 0.0001). HSCT patients also had significantly more nevi 45 mm in diameter and atypical nevi than controls. Factors associated with increased nevus count included malignant indication for HSCT, pretransplant chemotherapy, TBI exposure and myeloablative conditioning. A total of 16.5% of HSCT patients developed cancerous, precancerous lesions and/or lentigines. Our study suggests that pediatric HSCT recipients have an increased risk of benign and atypical melanocytic proliferations and nonmelanoma skin cancer that can manifest even during childhood.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (HSCT) can provide curative therapy for children with life-threatening malignant and nonmalignant conditions. As long-term survival improves, monitoring for late effects of HSCT becomes imperative.
Studies in large cohorts of HSCT survivors show an increased risk of melanoma and nonmelanoma skin cancer (NMSC) compared with the general population. [1] [2] [3] [4] [5] [6] [7] [8] Risk factors for subsequent skin cancers identified in these studies include young age (o 10 years) at HSCT and exposure to TBI, suggesting that pediatric HSCT survivors may be at particular risk for secondary skin cancers. 1, 3 However, these studies have been composed mostly of adult survivors, and the pediatric-specific data have been limited to case reports and case series. 9, 10 Thus, late effects of the skin that occur during childhood have not been a focus of study. Identification of children with precursor skin lesions such as excess benign nevi, atypical nevi, or actinic damage after HSCT may help guide providers to identify children at highest risk who require more vigilant skin surveillance.
In this study, we sought to investigate late effects of the skin in a cohort of children after HSCT. Using nevus count as a marker for melanoma risk, we determined the number and features of nevi in a large cohort of pediatric HSCT recipients. [11] [12] [13] [14] [15] We also identified risk factors associated with increased nevus count and atypical nevi. Lastly, we determined the incidence of cancerous, precancerous lesions, and lentigines and identified associated risk factors in this cohort.
MATERIALS AND METHODS

Study design
This study was a single-center, cross-sectional cohort study of pediatric HSCT recipients and matched controls seen over a 1.5-year period (October 2013 through April 2015) at Dana-Farber Cancer Institute/Boston Children's Hospital. IRB approval through the Dana-Farber Cancer Institute was obtained (Protocol 13-241). All patients and/or their legal guardians signed IRB-approved informed consents and approved publication of included photos.
Study participants
HSCT patients at our institution are advised to have annual dermatology visits. Study participants were recruited during their routine dermatology visits. Inclusion criteria for HSCT patients included history of allogeneic HSCT, age at HSCT ⩽ 21 years, time from transplant4365 days and English or Spanish speaking patients. Exclusion criteria included HSCT performed at another institution and disease relapse following last HSCT. Patients seen in the dermatology and primary care clinics at our institution were recruited as control study participants. Control patients were matched to HSCT patients by age (±1 year), sex and Fitzpatrick skin phototype (FPT) (I/II, III/IV, V/VI). The FPT is a widely used tool based on an individual's reaction to the sun in regards to sunburn and tanning. FPT is based on basic skin color and a patient's estimate of sunburning and tanning. FPT I/II patients have pale white skin color, sunburn easily and do not tan or tan with difficulty. FPT III/IV patients may have some sunburn but tan with ease. FPT V/VI patients have brown or black skin and rarely sunburn.
Exclusion criteria for controls included history of HSCT, systemic immunosuppression, or skin or other cancers, as well as nevi evaluation as reason for visit.
Study outcome measures and instruments
All study participants underwent full skin, hair and nail examination by a pediatric dermatologist (JTH, EBH). FPT was recorded. Evaluation of nevi was based on a prior study by Andreani et al., 17 in which nevus counts of the forearms (regularly sun-exposed area), buttocks (non-sun-exposed area), back and legs (intermittently sun-exposed area), palms and soles were performed. Overall, nevus count was defined as the sum of nevi counted on these locations. Nevi 45 mm and clinically atypical nevi (meeting two or more criteria: asymmetry, irregular borders, variation in color, different from other nevi) at any body site were recorded. Presence of precancerous lesions (including actinic keratosis or porokeratosis), solar lentigos and cancerous lesions was recorded.
Details of each patient's medical history, medications and transplant regimen were obtained during the visit and by medical record review. Fully matched patients had no identified mismatches at HLA-A,-B,-C and -DRB1 by high resolution typing, if the graft source was bone marrow or no identified mismatches at HLA-A,-B,-DRB1 by intermediate resolution typing if the graft source was cord blood. Myeloablative conditioning was defined as administration of TBI or alkylating agents at doses to ablate hematopoietic stem cells and prevent autologous hematologic recovery.
Statistical analysis
A Wilcoxon rank sum test was applied to compare the total nevus count and nevus count by body sites between HSCT patients and control patients. Within HSCT patients, a Wilcoxon rank sum test was used to identify the risk factors that were associated with developing more nevi, and univariate logistic regression models were applied to identify risk factors prognostic of developing atypical nevi, or of developing cancerous lesions, precancerous lesions or solar lentigines in HSCT patients. We adjusted our risk factor analysis by age based on the understanding that children acquire more nevi with age. Statistical tests were two-sided and considered statistically significant for P-values o0.05.
RESULTS
Demographics
Our cohort consisted of 85 HSCT patients and 85 matched controls. (Figure 1 ) HSCT were performed between 1994 and 2013; eight patients received two HSCTs. Median age at study visit was 13.8 years (1.4-26.1) in HSCT patients, with 69% of age o18 years and 92% of age o 21 years at study visit. Median time from date of HSCT to study visit was 3.6 years (1.2-16.2). The majority of HSCT patients were FPT I-IV. There were no statistically significant differences in age at visit, sex and FPT between HSCT patients and controls (Table 1) .
HSCT characteristics Median age at HSCT was 7.4 years (0.1-21.0). In all, 35.3% of patients were treated for nonmalignant conditions. A total of 83.5% received myeloablative conditioning. A total of 67% received TBI, with TBI doses ranging from 1200 to 1400 cGy in ablative transplants and 200 cGy in nonablative transplants. Other significant pre-and peri-transplant exposures in our cohort included pretransplant chemotherapy for leukemia and solid tumors ( In all, 15.3% of our cohort had a history of acute GvHD, 76.9% (10 out of 13) of whom had skin involvement. A total of 29.4% were diagnosed with chronic GvHD, 84% (21 out of 25) of whom had skin involvement. All patients received steroids as part of GvHD therapy. Other post-transplant complications included secondary non-cutaneous malignancies (5.9%) and subsequent solid organ transplantation (3.5%).
Nevus counts HSCT patients had significantly more nevi than control patients (median (range): 44 (0-150) vs 11 (0-94), P o0.0001). HSCT patients also had significantly more nevi on regularly sun-exposed (forearms), intermittently sun-exposed (back and legs) and nonsun-exposed areas (buttocks) as well as the palms and soles, than controls (Table 2) . HSCT patients had statistically significantly more nevi 45 mm and more clinically atypical nevi than controls (P o 0.0001 for both; Table 2 , Figures 2 and 3 ). There was a significantly higher percentage of HSCT patients than control patients with speckled lentiginous nevi (10.6 vs 0%, P = 0.003). The percentages of HSCT patients and control patients with café au lait macules were 7.1 and 2.4%, respectively (P = 0.3).
Factors significantly associated with increased overall nevus count within the cohort of HSCT patients included age ⩾ 10 years at HSCT, malignant indication for HSCT, pretransplant chemotherapy, exposure to TBI, myeloablative conditioning and history of sunburn since HSCT. (Table 3 ) After adjusting for age at visit, malignant indication for HSCT, pretransplant chemotherapy, exposure to TBI and myeloablative conditioning; all these factors remained significantly associated with increased overall nevus count (P = 0.05). Among those with exposure to myeloablative conditioning, patients receiving TBI as part of their conditioning regimen had significantly more nevi than those who did not receive TBI (median (range): 64 (3-150) vs 29 (0-144), P = 0.01). Comparison of 33 patients who received HSCT without pretransplant chemotherapy and matched controls revealed no significant differences in both overall nevus count (P = 0.2) and presence of atypical nevi (P = 0.1). Of 33 patients, 3 received TBI as part of their conditioning regimen and 19 out of 33 received a myeloablative conditioning regimen. Only 1 out of 33 patient received a myeloablative conditioning regimen containing TBI.
When divided by age at HSCT (o 10 years of age and ⩾ 10 years at HSCT), malignant indication for HSCT and exposure to TBI exposure were associated with increased nevus count only in those o 10 years of age at HSCT (P = 0.005, P o0.0001 and P = 0.08, P = 0.2, respectively). Analysis of myeloablative conditioning with TBI demonstrated a 12.1 (95% CI: 1.5, 98.6) times greater risk of the presence of atypical nevi than patients who did not receive TBI as a part of myeloablative conditioning. Of note, there was no statistically significant difference in post-HSCT follow-up time between patients who were transplanted at age o10 years and those who were transplanted at age ⩾ 10 years (P = 0.14).
Factors associated with presence of atypical nevi in HSCT patients included age ⩾ 10 years at HSCT (P = 0.04), malignant indication for HSCT (P = 0.003), exposure to TBI (P = 0.002), myeloablative conditioning (P = 0.004), cGvHD (P = 0.02) and cGvHD of the skin (P = 0.002) ( Table 4) . Comparison of 33 patients who received HSCT without pretransplant chemotherapy and matched controls revealed no significant difference in presence of atypical nevi (P = 0.1). Cancerous, precancerous lesions and lentigines In all, 16.5% (14/85) of HSCT patients had cancerous (SCC n = 4, BCC n = 1), precancerous lesions (actinic keratosis n = 4, porokeratosis n = 3), or solar lentigines (n = 9); some patients had more than one lesion (Figure 2) . The four HSCT patients with diagnoses of SCC and BCC have been previously reported. 10 None of these patients had an underlying diagnosis of Fanconi anemia or dyskeratosis congenita, conditions known to confer an increased risk of skin cancer.
Using a logistic regression model, the following factors were significantly associated with presence of cancerous lesions, precancerous lesions or solar lentigines: acute GvHD (P = 0.03), acute GvHD of skin (P = 0.04), chronic GvHD (P = 0.004), chronic GvHD of skin (P = 0.004), 412 months on immunosuppression (P = 0.0002), voriconazole use (P = 0.046), 46 months of voriconazole use (P = 0.0007), sunburns after HSCT (P = 0.004) and topical calcineurin inhibitors use (P = 0.02) ( Table 5 ). Of patients with a history of cancerous lesions, precancerous lesions, or solar lentigines and topical calcineurin inhibitor use, all patients also had a history of acute and/or chronic GvHD.
DISCUSSION
Our study found that children after HSCT have significantly more benign and atypical melanocytic nevi in sun-exposed and nonsun-exposed areas compared with a group of sex, age and skin phototype matched controls. These findings are important, as the presence of abundant benign melanocytic nevi and atypical nevi are established risk factors for subsequent development of melanoma. [11] [12] [13] [14] [15] We also found that 16.5% of our cohort had already developed cancerous or precancerous (actinic keratosis, porokeratosis) lesions or solar lentigines.
An increased incidence of melanoma and NMSC has been previously reported in adult HSCT recipients and adult childhood cancer survivors. [1] [2] [3] [4] [5] 8, [18] [19] [20] [21] In these studies, the low incidence of melanoma has precluded identification of melanoma-specific risk factors in this population. 2, 18 In adult HSCT recipients, risk factors for NMSC have been identified, including TBI-based myeloablative conditioning, cGVHD, prolonged immunosuppression, azathioprine use and voriconazole use. [1] [2] [3] [4] 22 However, reports of NMSC arising in childhood after HSCT or cancer therapy have been limited to case reports and small case series, and thus risk factors in this young age group are unknown. 9, 10 Our study is novel in that full skin examinations were performed by a dermatologist, allowing us to identify not only skin cancers but also precursor skin lesions. The higher prevalence of benign and atypical nevi, actinic keratoses and solar lentigines, allowed risk factor analysis. In addition, the majority of our cohort was of pediatric age at the time of data collection, providing the data regarding skin outcomes specific to children.
In our cohort, risk factors associated with increased nevus counts included malignant indication for HSCT, pretransplant chemotherapy, myeloablative conditioning and TBI. Similarly, the presence of clinically atypical nevi was associated with malignant indication, myeloablative conditioning and TBI. Although these risk factors often occur together, HSCT recipients receiving TBIbased myeloablative regimens had a significantly higher risk for atypical nevi compared with those not receiving TBI as part of their ablative conditioning. Conversely, we identified a low-risk subgroup of HSCT recipients, namely those who did not receive pretransplant chemotherapy, in whom we found no significant difference compared to controls in overall nevus count or presence of atypical nevi. Prior studies suggest that patients with malignant disease not undergoing HSCT are more likely to have melanocytic nevi than healthy controls. [23] [24] [25] A case-controlled study demonstrated that children who had completed chemotherapy had significantly more nevi than controls, while children in the midst of receiving chemotherapy had no increase in nevus counts. 26 Our data support these findings and suggest that exposure to cancer therapy likely plays a significant role in cutaneous nevogenesis in this population. However, it is important to note that patients receiving HSCT for nonmalignant indications are less likely to receive TBI or other myeloablative conditioning. Thus, our findings do not exclude the possibility that HSCT alone, particularly in those who receive TBI, is a potential risk factor for increased or aberrant nevogenesis.
We also identified risk factors for NMSC, precancerous lesions and lentigines, which included history of acute or chronic GVHD, prolonged immunosuppression, voriconazole use and history of sunburn after HSCT. The use of topical calcineurin inhibitors was also associated with occurrence of NMSC, precancerous lesions, and/or lentigines; however, all these patients also had GvHD of the skin, likely confounding this result. In large prospective studies, no association between topical calcineurin inhibitor use and development of skin cancer has been demonstrated. [27] [28] [29] [30] Like other organs, the skin develops and matures with age, with the majority of nevogenesis occurring in childhood. 31 The impact of young age on the incidence of late effects of cancer therapy has been shown in other organ systems. More significant cardiotoxicity has been reported in children who receive anthracyclines and radiation therapy, and there is an increased risk for osteochondromas in children exposed to TBI at age o 5 years. 32, 33 Similarly, one study of adult and pediatric HSCT recipients found an increase in nevus counts compared to age matched controls only among those age o20 years at HSCT. 17 In addition, studies of mixed age HSCT recipients demonstrate age o 10 years at HSCT and exposure to TBI as risk factors for NMSC. 1, 3 These data suggest that the childhood years may represent a time during which Age at transplant was also tested as a continuous variable in the univariate logistic model, P = 0.04. developing organs, including the skin, are more vulnerable to the effects of drug and radiation exposure. In addition, children may be at risk of thymic dysfunction after HSCT, contributing to the development of secondary malignancies. 34 Factors including cGvHD, malignant indication for HSCT, chemotherapy and radiation have been shown to adversely affect thymic function as measured by TCR excision circles. [35] [36] [37] [38] [39] [40] Interestingly, these same factors impacted both nevus counts and presence of atypical nevi in our cohort, suggesting that impaired immunosurveillance may be an integral component of benign and aberrant nevogenesis in HSCT patients.
The increased incidence of speckled lentiginous nevi in our cohort, compared to controls and the general population, may provide a clue to our understanding of cutaneous tumorigenesis in these patients. 41 Speckled lentiginous nevi result from postzygotic mutations occurring in a field of neural crest melanoblasts that subsequently result in nevogenesis, and more rarely, carcinogenesis. 41 Recently, a somatic activating mutation in HRAS has been identified in speckled lentiginous nevi, supporting this hypothesis. 42 RAS mutations have also been found in sun-exposed melanomas. 43 Whether nevogenesis occurs via second hit mutations or as an outcome of this primary mutation is unknown. It can be speculated that chemotherapy and radiation exposures may result in second hit mutations within precursor lesions, or perhaps these exposures, particularly at a young age, may alter immunosurveillance, resulting in melanocytic proliferations.
The cross-sectional design of our study precluded the prospective data. Additionally, our study had a relatively short median follow-up time after HSCT of 3.6 years, and it is possible that even greater effects may be seen with longer follow-up. Our cohort represented only one-third of children undergoing allogeneic HSCT during the study period, and may have been biased towards patients referred to dermatology due to dermatologic concerns. However, during the study period, dermatology evaluations were recommended for all children who received HSCT at our institution. Lastly, over 90% of our cohort was FPT I-IV and thus provides limited data on patients with darker skin types.
The 2015 guidelines for secondary solid cancer screening, following HSCT recommend that patients continue at least annual visits with a provider who performs a physical examination, as well as skin cancer awareness and photoprotection counseling. 44 In organ transplant recipients, educational interventions have improved photoprotection practices and skin cancer risk awareness. 45 We recommend annual full skin examinations for all pediatric HSCT recipients and dermatology referrals for children with risk factors, including malignant indication for HSCT, pretransplant chemotherapy, TBI myeloablative conditioning, exposure to TBI, cGvHD, prolonged immunosuppression or voriconazole use. We also recommend counseling of all HSCT patients on sun protection behaviors, including use of protective clothing, reapplication of sunscreen, and avoidance of mid-day sun. Larger prospective studies and long-term follow-up of this cohort are needed to confirm and expand on our findings. Age at transplant was also tested as a continuous variable in the univariate logistic model, P = 0.5. 
